A blood-based biomarker test aided diagnosis and clinical management of Alzheimer’s disease by detecting brain amyloidosis in symptomatic patients, researchers reported at the Clinical Trials for Alzheimer’s Disease annual meeting. Joel B. Braunstein, MD, MBA, co-founder and CEO of C2N Diagnostics in St. Louis, and colleagues developed PrecivityAD, a test that quantifies